Nowadays, minimal residual disease (MRD) is accepted as the strongest independent
prognostic factor in acute lymphoblastic leukemia (ALL). It can be detected by molecular …

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a
heterogeneous clinical course. With the advent of novel treatment options that will potentially …

Background T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this
study, we report our experience from 119 patients with T-PLL. Patients and methods We …

Abstract T-prolymphocytic leukemia (T-PLL) is a rare T-cell neoplasm with an aggressive
clinical course. Leukemic T-cells exhibit a post-thymic T-cell phenotype (Tdt−, CD1a …

Cancer is characterized by an extremely complex biological background, which hinders
personalized therapeutic interventions. Precision medicine promises to overcome this …

Minimal residual disease (MRD) is the most important independent prognostic factor in
acute lymphoblastic leukemia (ALL). Since it has been implemented into in treatment …

Purpose of Review T cell prolymphocytic leukemia (T-PLL) is a rare mature T cell tumor.
Available treatment options in this aggressive disease are largely inefficient and patient …

Minimal residual disease (MRD) in non-Hodgkin's lymphomas (NHLs) still represents matter
of interest and debate: indeed, the new available treatments offer higher rates of complete …

Abstract Minimal Residual Disease (MRD) is the most important independent prognostic
factor in acute lymphoblastic leukemia (ALL) and refers to the deep level of measurable …

ABSTRACT T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with
limited treatment options and poor long-term survival. Previous studies of allogeneic …